Prostate Cell News Volume 4.15 | Apr 26 2013

    0
    21

    Prostate Cell News 4.15 April 26, 2013

         In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  Prostate Cell News on Twitter

    TOP STORY

    Punctuated Evolution of Prostate Cancer Genomes
    Researchers sequenced the genomes of 57 prostate tumors and matched normal tissues to characterize somatic alterations and to study how they accumulate during oncogenesis and progression. By modeling the genesis of genomic rearrangements, they identified abundant DNA translocations and deletions that arise in a highly interdependent manner. [Cell] Abstract | Graphical Abstract | Press Release

    Free Wallchart | Assays for Human Mammary Stem and Progenitor Cells

    PUBLICATIONS (Ranked by impact factor of the journal)

    The Role of DAB2IP in Androgen Receptor Activation during Prostate Cancer Progression
    The authors showed that DAB2IP, a novel tumor suppressor in prostate cancer (PCa), can inhibit androgen-receptor (AR)-mediated cell growth and gene activation in PCa cells via distinct mechanisms. DAB2IP inhibits the genomic pathway by preventing AR nuclear translocation or phosphorylation and suppresses the non-genomic pathway via its unique functional domain to inactivate c-Src. [Oncogene] Abstract

    Increased Chemo-Sensitivity via Targeting Testicular Nuclear Receptor 4 (TR4)-Oct4-Interleukin 1 Receptor Antagonist (IL1Ra) Axis in Prostate Cancer CD133+ Stem/Progenitor Cells to Battle Prostate Cancer
    Prostate cancer (PCa) stem/progenitor cells are known to have higher chemo-resistance than non-stem/progenitor cells, but the underlying molecular mechanism remains unclear. The authors found the expression of TR4 is significantly higher in PCa CD133+ stem/progenitor cells compared to CD133 non-stem/progenitor cells. [J Biol Chem] Abstract | Full Article

    Identification of Drug Candidate against Prostate Cancer from the Aspect of Somatic Cell Reprograming
    Scientists used the EOS (Early transposon Oct4 and Sox2 enhancer) system to select human prostate cancer (PCA) cells expressing high levels of OCT4. The OCT4-expressing PCA cells selected using the EOS system showed increased tumorigenicity and high resistance to docetaxel, both in vitro and in vivo. [Cancer Sci] Abstract

    A Novel IgE Antibody Targeting the Prostate-Specific Antigen as a Potential Prostate Cancer Therapy
    Researchers explored the properties of a novel mouse/human chimeric anti-prostate-specific antigen IgE containing the variable regions of AR47.47 as a potential therapy for prostate cancer (PCa). Their goal was to take advantage of the unique properties of IgE in order to trigger immune activation against PCa. [BMC Cancer] Abstract | Full Article

    MicroRNA-205, a Novel Regulator of the Anti-Apoptotic Protein Bcl2, Is Downregulated in Prostate Cancer
    Scientists determined the expression of microRNA (miR)-205 in 111 archival samples of prostate carcinoma and found it to be strongly reduced in most samples, with a median expression level of 16% in comparison to benign tissue from the same patient. Lower miR-205 expression correlated significantly with tumor size and miR-205 levels decreased with increasing Gleason score from 7a=3+4 to 8=4+4. [Int J Oncol] Abstract

    Anti-Oxidative and Anti-Proliferative Activity on Human Prostate Cancer Cells Lines of the Phenolic Compounds from Corylopsis coreana Uyeki
    Fifteen phenolic compounds, including three caffeoyl derivatives, four gallotannins, three ellagitannins and five flavonoids, were isolated from an 80% MeOH extract of the leaves of Corylopsis coreana Uyeki. The anti-oxidative activities and the anti-proliferative activity on human prostate cancer cell lines were evaluated. [Molecules] Abstract | Full Article


    Androgens and Estrogens Stimulate Ribosome Biogenesis in Prostate and Breast Cancer Cells in Receptor Dependent Manner
    Researchers investigated the link between estrogen and androgen receptor signaling and the initial stage of ribosome biogenesis – transcription of rRNA genes. They discovered that estrogen or androgen treatment can positively regulate rRNA synthesis in breast and prostate cancer cells respectively and that this effect is receptor dependent. [Gene] Abstract

    CLINICAL RESEARCH

    Genetic Markers Associated with Early Cancer-Specific Mortality following Prostatectomy
    Researchers sought to identify novel effectors and markers of localized but potentially life-threatening prostate cancer, by evaluating chromosomal copy number alterations in tumors from patients who underwent prostatectomy and correlating these with clinicopathologic features and outcome. Abstract | Press Release

    The Prostate Cancer-Up-Regulated myc-Associated Zinc-Finger Protein (MAZ) Modulates Proliferation and Metastasis through Reciprocal Regulation of Androgen Receptor
    The role of MAZ in prostate cancer (PCa) tumorigenesis and its interaction with androgen receptor (AR), which is essential to PCa development in humans, were investigated. MAZ expression was found to be higher in clinical PCa specimens than in benign prostatic hyperplasia and adjacent normal tissues, and MAZ expression was positively correlated with AR expression, which was also observed in PCa cell lines. [Med Oncol] Abstract

    Reduction of Prostate Cancer Incidence by Naftopidil, an α1-Adrenoceptor Antagonist and Transforming Growth Factor-β Signaling Inhibitor
    Quinazoline-based α1-adrenoceptor antagonists are known to inhibit prostate tumor growth through induction of apoptosis. Researchers investigated the effect of a naphthalene-based α1-adrenoceptor antagonist, naftopidil, on prostate cancer incidence, apoptosis of prostatic cell and transforming growth factor-β signaling. [Int J Urol] Abstract

    PneumaCult™-ALI Medium for Bronchial Epithelial Cells: Watch the Video

    REVIEWS

    Dormancy in Solid Tumors: Implications for Prostate Cancer
    This review aims to identify currently known markers, mechanisms, and models of tumor dormancy, in particular as they relate to prostate cancer, and highlight current opportunities for advancement in our understanding of clinical cancer dormancy. [Cancer Metastasis Rev] Abstract

    Basic Research: iPSCs Created from Prostate and Urinary Tract Tissue
    Researchers have successfully generated human induced pluripotent stem cells (iPSCs) from normal aging human prostate and urinary tract tissue-producing Pro-iPSCs and UT-iPSCs, respectively. In contrast to conventional skin-derived iPSCs, Pro-iPSCs exhibited an enhanced ability to undergo prostate-epithelial-specific differentiation (characterized by induction of the androgen receptor and PSA). [Nat Rev Urol] Abstract

    Visit our reviews page to see a complete list of reviews in the prostate cell research field.

    INDUSTRY NEWS

    Profound Medical Announces Initiation of TULSA Clinical Trial for Treatment of Localized Prostate Cancer
    Profound Medical Inc. announced the commencement of its Health Canada approved, multi-center TULSA (Transurethral Ultrasound Ablation) clinical trial for its minimally invasive, novel ablation device used to facilitate prostate cancer treatment. [Profound Medical Inc.] Press Release

    Positive CHMP Opinion for XTANDI™ (Enzalutamide) in Advanced Prostate Cancer
    Astellas Pharma Europe Ltd., the European Headquarters of Tokyo-based Astellas Pharma Inc., and Medivation, Inc. have received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use, recommending European Commission approval for XTANDI capsules for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy. [Medivation, Inc.] Press Release

    From our sponsor:
    Looking for ALDH+ cancer stem cells?
    Watch a video to see how ALDEFLUORTM can help.

    POLICY NEWS

    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

    EVENTS

    NEW 2013 ASCO/AACR Workshop: Methods in Clinical Cancer Research
    July 27-August 2, 2013
    Vail, United States

    Visit our
    events page to see a complete list of events in the prostate cell community.

    JOB OPPORTUNITIES

    NEW Research Fellow – Medical Ultrasound (University of Dundee)

    PhD Studentship – Investigation into Chemokine Receptor Induced Cell Migration (University of East Anglia)

    Principal Investigator – Ca2+ Channels on Tumor Angiogenesis (Lille 1 University)

    Postdoctoral Research Associate – Prostate Cancer Research (University of Illinois at Chicago)

    PhD Studentship – The Role of STEAP2 in Prostate Cancer Invasion and Metastasis (Swansea University)

    Researcher – Prostate Cancer (Prostate Cancer UK)

    Postdoctoral Position – Tumor-Propagating Cells in Prostate Cancer (University of Georgia)

    Postdoctoral Position – Metabolic and Molecular Mechanisms of Advanced Prostate Cancer (Cleveland Clinic)

    Recruit Top Talent : Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

    Have we missed an important article or publication in Prostate Cell News? Click here to submit!

    Comments or Suggestions? Email info@connexoncreative.com with your feedback.

    Learn more about Prostate Cell News: Archives | Events | Contact Us